-

AM Best to Sponsor, Speak and Exhibit at The Insurer's European MGA Summit

LONDON--(BUSINESS WIRE)--AM Best’s Myles Gould, senior director, credit rating criteria research & analytics, will speak on a panel discussion during The Insurer's first-ever European MGA Summit, to be held 10-11 June, 2025, in Amsterdam.

The panel will take place on Wednesday, 11 June, at 11:00 a.m. DST and is titled, “Navigating regulatory complexity in a fragmented environment.” Panelists will discuss navigating a fragmented regulatory landscape and identify potential hurdles before they become hazards; compare regulatory approaches; and define best practices for supporting MGA growth. Additional panelists include Eva-Maria Barbosa, partner, Clyde & Co, and Martin Mankabady, partner, Eversheds Sutherland. Gould has been with AM Best since 2013 and is responsible for the development, testing and review of AM Best’s credit rating methodology and criteria. Formerly, he was AM Best’s international analytical lead for the Performance Assessment (PA) for Delegated Underwriting Authority Enterprises (DUAEs).

Additionally, AM Best is a gold sponsor and will exhibit at the event, which will be held at the Leonardo Royal Hotel Amsterdam. Summit delegates can use the opportunity to meet with various AM Best participants from their London and Amsterdam offices and discuss insurance credit ratings, and MGA performance assessments, insurance research, data, analysis and many more resources available to re/insurance professionals.

This is the first year of The Insurer’s European MGA Summit, which proposes a platform for European and international industry leaders to connect, exchange insights and explore innovative solutions in the growing DUAE market. The Insurer – a Reuters company – is a digital publisher covering the global property/casualty and reinsurance industries. To view more details, please visit the event overview.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2025 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Edem Kuenyehia
Director, Market Development
& Communications
+44 20 7397 0280
edem.kuenyehia@ambest.com

Industry:

AM Best

Release Versions
English
Hashtags
#insurance

Contacts

Edem Kuenyehia
Director, Market Development
& Communications
+44 20 7397 0280
edem.kuenyehia@ambest.com

Social Media Profiles
AM Best Rating Services on LinkedIn
AM Best Ratings Twitter
AM Best Co.
AM Best on YouTube
More News From AM Best

AM Best Assigns Credit Ratings to Charp Re, Ltd.

MEXICO CITY--(BUSINESS WIRE)--AM Best has assigned a Financial Strength Rating of B++ (Good) and a Long-Term Issuer Credit Rating (Long-Term ICR) of “bbb” (Good) to Charp Re, Ltd. (Charp Re) (Turks & Caicos Islands). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect Charp Re’s balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management (ER...

AM Best Revises Outlooks to Positive for FMH Insurance Group’s Members

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has revised the outlooks to positive from stable and affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Farmers Mutual Hail Insurance Company of Iowa and its reinsured affiliate, FMH Ag Risk Insurance Company. Both companies are domiciled in West Des Moines, IA and are collectively referred to as FMH Insurance Group (FMH).The Credit Ratings (ratings) reflect FMH’s overall balance sheet str...

Best’s Commentary: Health Insurers Evaluating Balance Between Pharmacy Costs and Long-Term Value of GLP-1 Therapies

OLDWICK, N.J.--(BUSINESS WIRE)--As pharmacy cost trends continue to rise and clinical evidence evolves, health insurers face a fundamental question on whether improvements in long-term morbidity and the potential for improved mortality outcomes ultimately justify significant investments in GLP-1 therapies, according to a new AM Best commentary. The Best’s Commentary, “GLP-1 Therapies: Evaluating the Balance Between Pharmacy Costs and Long-Term Value,” states that GLP-1 therapies have become one...
Back to Newsroom